Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.

Abstract: The present invention provides for methods of treating cognitive deficits resulting from interruption of blood supply and/or oxygen deficit by administering a therapeutically effective dose of a sulfonyl fluoride, such as methanesulfonyl fluoride and ethanesulfonyl fluoride. The underlying cause of the or oxygen deficit can be from stroke, trauma, carbon monoxide poisoning, and other poisonings. This method also includes co-administering with sulfonyl fluoride with a therapeutically effective dose of a second agent.

Abstract: Stem cells are exposed to disease condition (the OGD stroke model), that mimics the target disease (stroke), allowing the stem cells to exert better neuroprotective effects. Thus, the present technology demonstrates a disease-tailored stem cell therapy. The present invention discloses that the administration of a therapeutically effective amount of amnion derived stem cells concomitantly with a therapeutically effective dose of melatonin provides additive/synergistic neuroprotective effects. Moreover, the present invention offers an equally robust technology employing a receptor-regulated mechanism, whereby stem cells can be enhanced (melatonin treatment) over their basal level (lack of melatonin treatment), facilitating a regulation of stem cells.

Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.

Abstract: The subject invention pertains to uses of delta opioid peptides and salts thereof for promoting neurogenesis and to pharmaceutical compositions containing such peptides and salts as active ingredients. Specifically exemplified herein is [D-Ala2,D-Leu5]enkephalin (DADLE) and salts thereof. The peptides of the present invention upregulate glial cell-derived neurotrophic factor (GDNF) in the nervous system and are useful for prevention and treatment of diseases and conditions associated with neurological injury, in particular, stroke.

Abstract: The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport.

Abstract: The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport.

Abstract: A method of producing a sustained localized immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the tissue.

Abstract: The present invention provides for methods of treating cognitive deficits resulting from interruption of blood supply and/or oxygen deficit by administering a therapeutically effective dose of a sulfonyl fluoride, such as methanesulfonyl fluoride and ethanesulfonyl fluoride. The underlying cause of the or oxygen deficit can be from stroke, trauma, carbon monoxide poisoning, and other poisonings. This method also includes co-administering with sulfonyl fluoride with a therapeutically effective dose of a second agent.

Abstract: The administration of a therapeutically effective amount of melatonin is an effective method for treating paralysis of the extremities caused by cerebral infarction.

Abstract: The administration of a therapeutically effective amount of melatonin is an effective method for treating paralysis of the extremities caused by cerebral infarction.

Abstract: A method of generating in situ trophic factor production by transplanting Sertoli cells into a tissue in need of trophic factors of a mammal, the cells creating trophic factors in situ.

Abstract: A method of enhancing the viability of cryopreserved cells is culturing Sertoli cells in media to produce preconditioned media and adding the preconditioned media to the cells to be cryopreserved. The cells are then cryopreserved. Alternatively, a method of enhancing the viability of cryopreserved cells is co-culturing Sertoli cells and cells to be cryopreserved in media and cryopreserving both.

Abstract: A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or cryopreservation.

Abstract: A method of producing a sustained localized brain immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the brain tissue.

Abstract: A method of generating in situ trophic factor production by transplanting Sertoli cells into the central nervous system of a mammal, the cells creating trophic factors in situ.